Novus Biologicals launches new antibody for Turner Syndrome Research

USP9x is an ubiquitin-specific protease involved in the removal and recycling of ubiquitin from proteins degraded in proteasomes.  Novus Biologicals just introduced a new anti-USP9x antibody (catalog # NBP1-48321), as well as the USPx blocking peptide (catalog # NBP1-48321PEP).

The immunogen to which this rabbit polyclonal USP9x antibody was made is a genomic peptide, which was made within residues 1150-1300 of the human Usp9X protein.  SDIX's Genomic Antibody TechnologyTM was used to produce this antibody.  It cross-reacts with human, mouse and rat, and also has 80% sequence identity with Zebrafish.  This USP9x antibody is useful for immunocytochemistry and Western blot, where it recognizes a band at ~270kDa.

USP9x is located on the X-chromosome but escapes X-inactivation, and defects in the USP9X protein may cause gonadal degeneration in Turner syndrome. Thus, Novus' new USP9x antibody is useful for the study of Turner syndrome and the Ubiquitin Proteasome Pathway.  Also, as a deubiquitinating enzyme, USP9x has a critical function in tight junction biogenesis by controlling the levels of the exchange factor for Arf6, a protein shown to facilitate tight junction formation during a narrow temporal window preceding the establishment of cell polarity (PMID: 20339350).

Novus provides other USP9x antibodies, proteins and RNAi which can be found here. USP9x -related products are also available from Novus, including: Gelsolin, UCHL3, and beta Catenin.


For more information on this new USP9x antibody or to inquire about product collaborations, please contact the Novus Product Development Team by calling 303-730-1950 or via e-mail at

Release Date: 
Friday, October 8, 2010 - 06:00